Citations

Clear

1280 citation(s) found for "Bu, Hong".

Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real‐World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab
Rimini, Margherita , Lamarca, Angela, Ikeda, Masafumi, Kim, Jin Won , Vogel, Arndt, Peeters, Frederik , Pinato, David J., Pircher, Chiara, Martirena, A. , Perkhofer, Lukas , Pinto, C. , Kang, Beodeul, Pastorino, Alessandro , Changhoon, Yoo, Rodriquenz, Maria Grazia , Scartozzi, Mario, Zumstein, Lucrezia , Ghidini, Michele, Aprile, Giuseppe , Spinelli, Gian Paolo , Yung‐Yeh, Su, Bolnykh, Iakov, Lancianese, Alessia , Satake, Tomoyuki, Lavacchi, Daniele, Passeri, Laura , Kang, Minsu, Viola, Massimo, Persano, Mara , Balsano, Rita , Ratti, Francesca, Rimassa, Lorenza , Kim, Jin Won , Vivaldi, Caterina , Formica, Vincenzo , Farinea, Giovanni , Prager, Gerald W , Chan, Stephen L , Niger, Monica , Fornaro, Lorenzo , Casadei-Gardini, Andrea , Rimassa, Lorenza , Saborowski, Anna , Rimini, Margherita , Lamarca, Angela , Ikeda, Masafumi , Abidoye, Oluseyi , Lucchetti, Jessica , Antonuzzo, Lorenzo , Vogel, Arndt , Nichetti, Federico , Pressiani, Tiziana , Vivaldi, Caterina , Rapposelli, Ilario Giovanni , Braconi, Chiara , Pinato, David J. , Tamburini, Emiliano , Pircher, Chiara , Tamberi, Stefano , Castet, Florian , Verrico, Monica , Parisi, Alessandro , Couto, Nuno , Chon, Hong Jae , Landriscina, Matteo , Finkelmeier, Fabian , Oneda, Ester , Avallone, Antonio , Dell’Aquila, Emanuela , Kim, Il Hwan , Garajova, Ingrid , Kang, Beodeul , Corallo, Salvatore , Fenocchio, Elisabetta , Diana, Anna , Schirripa, Marta , Scartozzi, Mario , Ghidini, Michele , Prager, Gerald W. , Chan, Stephen L. , Bekaii‐Saab, Tanios , Ferrara, Michele , Kang, Minsu, Bozzarelli, Silvia , Masi, Gianluca , Niger, Monica , Lonardi, Sara , Salani, Francesca , Camera, Silvia , Ratti, Francesca , Fornaro, Lorenzo , Casadei‐Gardini, Andrea

Mayo Clinic

International Journal of Cancer | July 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ijc.70641 | PMID 42524843 Get It

ABSTRACT Surgery after response to first‐line chemoimmunotherapy may offer a potential curative option for patients with locally advanced biliary tract cancer (BTC) initially considered unresectable. However, robust real‐world evidence in this setting remains limited. We retrospectively analyzed patients with locally advanced BTC treated with first‐line cisplatin, gemcitabine, and durvalumab (CGD) across 55 centers in 12 countries. Endpoints included overall survival (OS), progression‐free survival (PFS), disease‐free survival (DFS) among resected patients, objective response rate (ORR), and the prognostic impact of surgery. A multivariable logistic regression model was developed to predict surgical conversion using baseline clinical and laboratory variables. Among 1358 screened patients, 219 had locally advanced disease and were included in the analysis. Median follow‐up was 14.5 months. ORR was 34.6%, with median PFS and OS of 10.0 and 20.7 months, respectively. Twenty‐four patients (10.9%) underwent surgical resection after systemic therapy. Median OS was 22.5 months in resected patients versus 19.9 months in those who did not undergo surgery. Median DFS after resection was 15.8 months. Pathological lymph node involvement was independently associated with shorter DFS. Larger baseline tumor size correlated with higher odds of radiological response but not with OS. An exploratory elastic‐net model retained four baseline variables and showed moderate discriminative ability for surgical conversion, with an apparent AUC of 0.72 and an optimism‐corrected AUC of 0.65. First‐line CGD enabled secondary resection in approximately 11% of patients with locally advanced BTC. A simple baseline model may support patient selection for conversion surgery, although prospective validation is needed.
Comparison of Factors Associated With 30‐Day and 90‐Day Readmission Among a Global Cohort of Patients Hospitalised With Cirrhosis
Haktanıyan, Büşra, Choudhury, Ashok , Wong, Florence , Kamath, Patrick S. , Topazian, Mark , Hayes, P C, Álvares‐da‐Silva, Mário Reis , Torre, Aldo , Silvey, Scott, Bajaj, Jasmohan S. , Investigators, CLEARED, Barutçu, Sezgin , Fisseha, Henok , Idilman, Ramazan , Haktaniyan, Busra , Chaudhary, Ashok , Wong, Florence , Kamath, Patrick S , Xie, Qing , Topazian, Mark D , Alvares-da-Silva, Mario Reis , Torre, Aldo , George, Jacob , Seto, Wai-Kay , BUSH, BRIAN J. , Thacker, Leroy R , Bajaj, Jasmohan S , Fisseha, Henok , Idılman, Ramazan , George, Jacob , Seto, Wai‐Kay , Silvey, Scott , Thacker, Leroy R.

Mayo Clinic

Liver International | July 29, 2026 | Volume: 46 | Issue: 9 | Pages: No page available

10.1111/liv.70804 | PMID 42522657 Get It

ABSTRACT Background and Aims It remains unclear whether different factors influence 30‐ and 90‐day readmission rates. We identified predictors of 90‐day mortality in a global cohort of hospitalised patients with cirrhosis. Methods Variables associated with 30‐ and 90‐day post‐discharge readmission, liver transplantation (LT), and mortality were compared in prospectively enrolled, non‐electively hospitalised adult patients with cirrhosis. Results We enrolled 4208 patients from 125 centres across 37 countries. Alcohol‐related liver disease was the most common aetiology of cirrhosis (40%), followed by hepatitis B virus infection (21%); 47% were readmitted, 8% received liver transplantation (LT), and 23% died within 90 days post‐discharge. In multivariable analysis, country income was significantly associated with both 30‐ and 90‐day readmission rates, the receipt of LT, and mortality within 30 and 90 days post‐discharge (all p ‐values < 0.001). Independent predictors of higher rates of 30‐ and 90‐day readmissions, respectively, were disease severity ( p < 0.001, p = 0.003), prior ascites ( p = 0.025, p = 0.016), prior hospitalisation ( p < 0.001), hyponatremia ( p < 0.001, p = 0.008), and in‐hospital vasopressor use ( p = 0.002, p = 0.011). Prior variceal bleeding independently predicted higher 90‐day readmission rates, whereas age, disease severity, mechanical ventilation, and in‐hospital vasopressor use (all, p < 0.001) increased odds of 30‐ and 90‐day post‐discharge death. Additionally, admission ( p = 0.011) and nosocomial ( p = 0.022) infections increased the odds of 90‐day post‐discharge death. Conclusion In a global cohort of hospitalised patients with cirrhosis, patients in high‐income countries exhibited the highest rates of 30‐ and 90‐day readmission, alongside lower mortality rates and a higher incidence of LT. Variables that predict 30‐day readmission also predicted 90‐day readmission. Understanding these disparities is essential for achieving health equity.
Global multicenter validation of noninvasive fibrosis assessment pathways in MetALD and ALD
Gu, Hyundam , Diaz, Luis Antonio, Baeza, Natalia, Idalsoaga, Francisco, Zheng, Ming‐Hua , Maiwall, Rakhi , Sarin, Shiv K., Kulkarni, Anand V., Ramyasri, Ramagundam, Tijera, Fátima Higuera de La, Pinto, Helena , Carvalhana, Sofia, Fernandes, Rita , Khan, Mohammad Qasim , Alazawi, William, Li, Wenhao, Temperley, Laura , Marti-Aguado, David, Gratacós-Ginès, Jordi, Montes, Pedro, Yip, Terry Cheuk‐Fung , Wong, Vincent Wai-Sun, Villela-Nogueira, Cristiane, Leite, Nathalie, Salles, Gil F. , Cardoso, Claudia Regina Lopes, Contreras, Daniza, Galimberti, Alceo, Bessone, Fernando, Valentin-Cortez, Francisco J , Mijangos-Trejo, Alejandra, Chavéz-Tapia, N, Simian, Daniela , Gil, Pamela, Mattos, Ângelo, Acuña, Johana , Araujo, Roberta Chaves, Ferraz, Igor Lima, Marrugo, Katherine, Torres, A , Torres, Juan Diego , Valdes, V., Córdova, Jacqueline, Mendizabal, Manual, Couto, Cláudia Alves , Cotter, Thomas G., Anouti, Ahmad , Rady, Elias D. , Patel, Sheel , Singal, Ashwani K., Parker, Richard, Ibrahim, Mohamad Ali , Jalal, Prasun K., Noureddin, Mazen, Alkhouri, Naim , Kamath, Patrick S. , Sanyal, Arun, Sterling, Richard K., Ajmera, Veeral, Loomba, Rohit, Arrese, Marco, Bataller, Ramón , Arab, Juan Pablo, Jalal, Prasun K , Cuyas, Berta , Cheuk-Fung Yip, Terry , Zheng, Ming-Hua , Díaz, Luis Antonio , Baeza, Natalia , Idalsoaga, Francisco , Zhou, Xiao-Dong , Sarin, Shiv Kumar , Kulkarni, Anand V., Ramyasri, Ramagundam, Carvalhana, Sofia , Alazawi, William , Li, Wenhao , Aguado, David Martí , Gratacós‐Ginès, Jordi , Pose, Elisa , Poca, María , Cuyàs, Berta , Barreyro, Fernando Javier , Ayares, Gustavo , Wong, Vincent Wai‐Sun , Wong, Grace Lai‐Hung , Lai, Jimmy Che‐To , Cardoso, Claudia R.L. , Velasco, J.A. Velarde-Ruiz , Galimberti, Alceo, Bessone, Fernando , Chávez-Tapia, Norberto Carlos , Ridruejo, Ezequiel , Peralta, Mirta , Roblero, Juan Pablo , El‐Kassas, Mohamed , Araújo, Roberta Chaves , Marrugo, Katherine , Mendizabal, Manuel , Cançado, Guilherme Grossi Lopes , Cotter, T G , Dahshi, Hamza , Singal, Ashwani K. , Pekarska, Katrīna , Jalal, Prasun K. , Castro-Narro, Graciela E , Noureddin, Mazen , Dunn, Winston , Sanyal, Arun J. , Sterling, Richard K. , Ajmera, Veeral , Loomba, Rohit , Arrese, Marco , Arab, Juan Pablo

Mayo Clinic

Hepatology Communications | July 28, 2026 | Volume: 10 | Issue: 8 | Pages: No page available

10.1097/hc9.0000000000001020 | PMID 42520161 Get It

Background: Noninvasive tests are well validated in metabolic dysfunction–associated steatotic liver disease, but evidence in metabolic dysfunction and alcohol-associated liver disease (MetALD) and alcohol-associated liver disease (ALD) is limited. We evaluated noninvasive test–based clinical care pathways for fibrosis risk stratification in MetALD and ALD. Methods: This is a multinational, multicenter, cross-sectional study across 35 centers in 16 countries (2013–2025), including adults with MetALD or ALD. Fibrosis was assessed by liver biopsy and/or vibration-controlled transient elastography (VCTE). In biopsy-proven participants, we analyzed the sequential pathway (Fibrosis-4 [FIB-4] first, followed by VCTE for indeterminate FIB-4) to identify advanced fibrosis (≥F3). Diagnostic accuracy was assessed using the AUC. Results: Among 893 participants (41.3% MetALD and 58.7% ALD), the median age was 52 [43.0–61.0] years, and 79.4% were male. The estimated prevalence of advanced fibrosis was 45% (32.2% in MetALD and 54.0% in ALD). Participants with MetALD had a more dysmetabolic profile but lower fibrosis stages than ALD. Among biopsy-proven participants, FIB-4 AUC was 0.720, and VCTE AUC was 0.833. FIB-4 performed better in MetALD than ALD (AUC 0.773 vs. 0.540), while VCTE accuracy was similar across groups. In the sequential pathways, the false-negative rate for advanced fibrosis (misclassified as low risk) was 6.8% (4.9% MetALD and 11.3% ALD). Conclusions: In biopsy-proven patients, FIB-4 performance was acceptable in MetALD but substantially weaker in ALD. The standard 2-step pathway performed adequately in MetALD but missed a clinically meaningful proportion of advanced fibrosis in ALD.
The Genomic Landscape and Treatment Outcomes Associated with CDKN2A/MTAP Loss in Patients with Non–Small Cell Lung Cancer
Vokes, Natalie I. , Symons, Jessica L. , Rhead, Brooke , Hong, Lingzhi , Shah, Pooja A. , Lai, Zhongwu , Zhu, Zhou , Treviño, Santiago , Iorgulescu, J. Bryan , Wu, Jia , Leventakos, Konstantinos , Zhu, Zhou , Bryan, Julian , Zhang, Jianjun , Gibbons, Don L , Heymach, John V , Stewart, Ross , Iyer, Sonia , Leventakos, Konstantinos , Fragkogianni, Stamatina , Chao, Calvin Y. , Rodon, Jordi , Zhang, Jianjun , Heymach, John V. , Fragkogianni, Stamatina , Vokes, N. , Wu, Jia

Mayo Clinic

Clinical Cancer Research | July 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: OF1-OF14

10.1158/1078-0432.ccr-26-0771 | PMID 42507545 Get It

Abstract Purpose: Homozygous deletion of the 9p21 locus, containing CDKN2A/B and MTAP [CDKN2A/MTAP deletion (CMdel)], underlies emerging therapeutic strategies, including PRMT5/MAT2A inhibition. The clinicogenomic context and treatment outcome associations of CMdel in non–small cell lung cancer (NSCLC) remain incompletely defined. Experimental Design: We analyzed Tempus Lens records with paired DNA (xT) and RNA (xR) sequencing. After quality filtering (purity ≥40%), 16,947 patients were included in the primary dataset, and 10,996 were included in the validation dataset and stratified by deletion status [CMdel vs. CM wild-type (CMwt)]. IFN status was defined by IFN-kappa (IFNK) expression [log2(TPM + 1)] using the 25th percentile of CMwt as the threshold. Immune composition was inferred by quanTIseq. First-line regimens were grouped as immune checkpoint inhibitor (ICI) monotherapy, ICI chemotherapy, chemotherapy, or tyrosine kinase inhibitors (TKI). Best response and time to next treatment (TTNT) with risk-set adjustment and 18-month truncation were assessed. Results: CMdel occurred in 11.7% (n = 1,991) and 15% (n = 1,676), respectively, and was enriched in mucinous histology, stage IV disease, and never smokers. CMdel was associated with EGFR, TERT, and SMARCA4 alterations, whereas CMwt was associated with RB1, SETD2, and ARID2. More than 50% of CMdel tumors harbored targetable coalterations, enriched in EGFR/ALK/RET and relatively depleted in KRAS. CMdel tumors exhibited lower PD-L1, mutation burden, and immune infiltration. TTNT did not differ by CM status for ICI monotherapy or TKI but was shorter in CMdel for ICI chemotherapy and chemotherapy. Discordant and broad deletions were less common and had weaker TTNT association. IFNK-low expression marked immune-excluded subgroups with worse treatment outcomes. Conclusions: CDKN2A/MTAP loss defines a prevalent, genomically distinct NSCLC subset enriched in actionable drivers. CMdel associates with worse outcomes to ICI/chemotherapy-containing regimens. These findings highlight convergent biology at 9p21 and support biomarker-guided development of PRMT5/MAT2A inhibitors in MTAP-deleted NSCLC.
Bridging Conservative Management With Injectable Orthobiologic Therapies: Proceedings of the International Consensus Meetings on Cartilage Repair of the Ankle
Tham, Alexander, Rubin, Jared, Butler, James J., Gauthier, Paloma , Kennedy, John G. , Adams, Samuel B., Andrews, Carol L., Batista, Jorge , Baur, Onno L., Bayer, Stephen, Becher, Christoph, Berlet, Gregory C. , Boakye, Lorraine AT, Buda, R, Calder, James D. F., Dahmen, Jari , D’Hooghe, Pieter, DiGiovanni, Christopher W., Ehlers, M. , Ferkel, Richard D. , Ferkel, Eric, Ferrao, Paulo N. F., Giza, Eric , Gianakos, Arianna L., Glazebrook, Mark, Gomaa, Mohamed, Görtz, Simon, Haleem, Amgad M. , Hamid, Kamran S. , Hangody, László, Haverkamp, Daniel, Hertel, Jay, Hintermann, Beat, Hogan, MaCalus V., Hunt, Kenneth J., Hurley, Eoghan T., Karlsson, Jon, Kearns, Stephen R. , Kerkhoffs, Gino M. M. J., Kim, Hak Jun , Kong, Siu Wah, Krebsbach, Sebastian, Labib, Sameh A. , Lambers, Kaj T. A. , Lee, Jin Woo, Lee, Keun Bae, Ling, Jeffrey S., Longo, Umile Giuseppe, Marangon, Alberto, McCollum, G, McCullough, Kirk, Mittwede, Peter N. , Murawski, Christopher D. , Nicolescu, Raluca, Niemeyer, Philipp, Nunley, James A., O'Malley, Martin, Ortiz, Cristian, Osei-Hwedieh, David O. , Paul, Jochen , Pearce, Christopher J., Pereira, Hélder , Phadke, Rohan , Prado, Marcelo P. , Raikin, Steven M., Reilingh, Mikel L., Robert, Guillaume , Lc, Schon, Simpson, Helene, Smyth, Niall A. , Sofka, Carolyn M., Spennacchio, Pietro, Stone, James W., Takao, M, Tanaka, Yasuhito, Thermann, Hajo, Thordarson, David B. , Rs, Tuan, Valderrabano, Victor, Bergen, Christian J. A. van, Dijk, Pim A. D van, Dijk, Niek van, Vannini, Francesca, Vaseenon, Tanawat , Volesky, Monika , Walls, Raymond C., Walther, Markus, Wiewiorski, Martin, Xu, Xiangyang, Yasui, Youichi , Yinghui, Hua, Yoshimura, Ichiro, Younger, Alastair , Zdanowicz, Urszala, Zhang, Zijun, Adams, Samuel B. , Clanton, Thomas O , Dahmen, Jari , Ehlers, Mallory , Hannon, Charles P , Labib, Sameh A , Popchak, Adam , Robert, Guillaume , Smyth, Niall A , Tham, Alexander , Rubin, J Peter , Butler, James J., Angthong, Chayanin , Becher, Christoph, Boakye, Lorraine A. T. , Buda, Roberto , Calder, James D. F. , Canata, Gian Luigi , Carreira, Dominic S. , Dahmen, Jari , d’Hooghe, Pieter P. R. N. , DiGiovanni, Christopher William , Dombrowski, Malcolm E. , Ferkel, Eric I. , Ferrao, Paulo N. F. , Gianakos, Arianna L. , Glazebrook, Mark Anthony , Gomaa, Mohamed, Hannon, Charles P. , Haverkamp, Daniël , Hintermann, Beat , Hogan, MaCalus Vinson , Hunt, Kenneth John , Hurley, Eoghan T. , Karlsson, Jon, Kerkhoffs, Gino M. M. J. , Krebsbach, Sebastian , Lee, Jin Woo , Longo, Umile Giuseppe , Mitchell, Adam W. , Nehrer, Stefan , Niemeyer, Philipp , Nunley, James A. , O’Malley, Martin , Pearce, Christopher Jon , Pereira, Hélder , Raikin, Steven M. , Rothrauff, Benjamin B. , Schon, Lew Charles , Spennacchio, Pietro , Sullivan, Martin, Tanaka, Yasuhito , Valderrábano, Víctor , Dijk, Pim A. D. van , Vannini, Francesca , Walther, Markus , Wiewiorski, Martin J., Xu, Xiangyang , Yoshimura, Ichiro , Zhang, Zijun

Mayo Clinic

Foot & Ankle Specialist | July 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/19386400261456925 | PMID 42495946 Get It

Background The management of osteochondral lesions of the talus (OLT) is challenging, with 2 main options being conservative and surgical management. Orthobiologic therapies come to bridge the gap between these 2 options; however, inconsistencies in indication, composition, and heterogeneous evidence limit clinical decision-making. To address these challenges, 3 International Congress Meetings on Cartilage Repair of the Ankle were convened in Pittsburgh, USA (2017), Dublin, Ireland (2019), and New York, USA (2025) to establish agreement on the role of conservative management and injectable orthobiologic strategies in the treatment of OLT. Methods Seventy-five multidisciplinary experts from over 25 countries and 1 territory participated in a structured Delphi-based consensus process. Blinded surveys, structured questionnaires, and in-person discussions were used to develop and refine statements, supported by literature review and graded evidence (A1–E). Consensus strength was defined as consensus (51%-74%), strong consensus (75%-99%), or unanimous (100%) Results In total, 29 consensus statements were achieved across the 3 meetings. Strong agreement was reached regarding indications and expected outcomes of conservative management, including the role of immobilization and appropriate timing for surgical intervention. Orthobiologic injections, including platelet-rich plasma, concentrated bone marrow aspirate, and hyaluronic acid, were considered appropriate in select patients with persistent symptoms, although no superiority was demonstrated among formulations, preparation methods, or injection strategies. When used as adjuncts to surgical procedures, orthobiologics may improve radiological outcomes, with limited evidence for improvement in clinical outcomes. Technical considerations, including preferred harvest sites and a lack of standardized preparation protocols, were identified, along with key principles for patient counseling Conclusion These international consensus statements establish a standardized framework for the conservative management and use of injectable orthobiologic therapies in OLT. By clarifying indications, technical considerations, and current limitations, this work aims to improve consistency in clinical practice, guide treatment decision-making, and inform future research.
Consensus Guidance for Beta‐Lactam Antibiotic Dose Individualization in Acutely Ill Patients: Endorsed by the American College of Clinical Pharmacy, European Society of Clinical Microbiology and Infectious Diseases, European Society of Clinical Microbiolog
Frazee, Erin N. , McCreary, Erin K. , Mangalore, Rekha Pai , Girdwood, Sonya Tang , Arriola, Rebecca, Bens, Cynthia, Bonomo, Robert A. , Edginton, Andrea N. , Hong, Lisa , Huttner, Angela , Maranchick, Nicole, Röhr, Anka C., Zuluaga, Andrés F. , Frazee, Erin N , Pai Mangalore, Rekha , Tang Girdwood, Sonya , Hong, Lisa T , Koch, Birgit C P , Maranchick, Nicole , Neely, Michael N , Peloquin, Charles A , Rao, Gauri G , Roberts, Jason A , Scheetz, Marc H , Schuetz, Audrey N , Yarnold, Paul R , Zuluaga, Andres , Rhodes, Nathaniel J , Bonomo, Robert A , McCreary, Erin K , Neely, Michael , Peloquin, Charles A. , Röhr, Anka C., Scheetz, Marc H. , Schuetz, Audrey N. , Rhodes, Nathaniel J.

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | July 23, 2026 | Volume: 46 | Issue: 8 | Pages: No page available

10.1002/phar.70181 | PMID 42487243 Get It

ABSTRACT Beta‐lactam antibiotics (beta‐lactams) are first‐line treatments for most major infectious syndromes in acutely ill patients, with in vitro activity against common pathogens, demonstrated efficacy in trials, and a perceived low risk of adverse effects. The current dosing approach, informed by population‐level data, tends to be simplistically reduced to a “one size fits all” dosing method which only accounts for body weight (i.e., in pediatrics) and end organ function to estimate drug clearance (e.g., estimated glomerular filtration rate); this approach results in substantial variability in observed serum concentrations in acutely ill patients, which can compromise real‐world effectiveness and safety. Beta‐lactam dose individualization, therefore, defined as a dosing regimen for one patient informed by measured concentrations from that patient, has been recommended in international clinical guidelines. Comprehensive guidance on best practices for beta‐lactam dose individualization is lacking. To address this knowledge gap and develop guidance, a multidisciplinary panel of international experts was assembled from the disciplines of infectious diseases, critical care, pharmacometrics, and laboratory medicine, representing both adults and pediatrics. The panel systematically evaluated the literature, using the GRADE approach where feasible, to address broad thematic questions pertaining to whether beta‐lactam dose individualization should be pursued, for what indications beta‐lactam dose individualization is warranted, and the most critical considerations and best practices for implementation of beta‐lactam individualization. The resultant consensus recommendations will equip healthcare professionals caring for acutely ill patients treated with beta‐lactam therapy with the evidence and tools necessary to guide optimal use of beta‐lactam dose individualization.
Primary Aldosteronism Medical Treatment Outcomes (PAMO) Beyond 12 Months
Yang, Jun , Goi, Jessica , Burrello, Jacopo , Reincke, Martín , Adolf, Christian, Brüdgam, Denise , Li, Qifu , Song, Ying , Hu, Jinbo , Yang, Shumin , Satoh, Fumitoshi , Ono, Yoshikiyo , Libianto, Renata , Nayak, Drishya , Vaidya, Anand , O’Toole, Samuel , Larose, Stéphanie , Nakai, Kazuki , Nishikawa, Tetsuo , Ladygina, D. O. , Fardella, Carlos , Mulatero, Paolo , Drake, William M., Varsani, Chetna, Wu, Xilin , Stowasser, Michael , Li, Nanfang , Zhu, Qing , Hong, Namki , Nayak, Drishya , Puar, Troy H , Wu, Vin-Cent , Vaidya, Anand , Araujo-Castro, Marta , Kocjan, Tomaz , O'Toole, Samuel Matthew , Hundemer, Gregory L , Ragnarsson, Oskar , Lacroix, Andre , Larose, Stephanie , Nakai, Kazuki , Nishikawa, Tetsuo , Ladygina, Daria , Turcu, Adina F , Fardella, Carlos E , Uslar, Thomas , Quinkler, Marcus , Mulatero, Paolo , Pintus, Giovanni , Rossi, Gian Paolo , Hahner, Stefanie , Amar, Laurence , Brown, Morris Jonathan , Wu, Xilin , Young, W F , Williams, Tracy Ann , Fuller, Peter J , Yang, Jun , Stowasser, Michael , Hong, Namki , Wu, Vin‐Cent , Araujo‐Castro, Marta , Kocjan, Tomaž , Lacroix, André , Turcu, Adina F. , Vibhatavata, Peeradon , Quinkler, Marcus , Rossi, Gian Paolo , Hahner, Stefanie , Drake, William, Young, William F. , Williams, Tracy Ann

Mayo Clinic

Hypertension | July 22, 2026 | Volume: 83 | Issue: 9 | Pages: No page available

10.1161/hypertensionaha.126.27431 | PMID 42483794 Get It

BACKGROUND: Primary aldosteronism (PA) is a common and treatable cause of hypertension, yet data on the durability of medical treatment response beyond the first year are limited. Using the PA medical treatment outcomes framework, we evaluated long-term biochemical and clinical outcomes and factors associated with treatment response. METHODS: We conducted an international, multicenter, observational cohort study across 27 centers on 4 continents. Adults with PA treated with mineralocorticoid receptor antagonists and/or epithelial sodium channel blockers between 2016 and 2021 were included if follow-up data were available at ≥12 months. Biochemical and clinical responses were classified as complete, partial, or absent using PA medical treatment outcomes criteria. Ordinal logistic regression identified determinants of a favorable treatment response. RESULTS: The cohort included 1292 patients (47.5% women, mean age 52 years) with a median follow-up of 34 months (interquartile range, 21–51). At ≥12 months, 58.3% achieved a complete biochemical response, and 20.8% achieved a complete clinical response, with only 5% showing no response. Determinants of a favorable biochemical response included lower aldosterone and lateralization index, and higher renin and potassium levels at baseline. In those taking spironolactone, a higher daily dose was also associated with a favorable biochemical response. Determinants of a favorable clinical response included female sex, lower body mass index, shorter duration of hypertension, and absence of hypertension-mediated organ damage. CONCLUSIONS: Targeted medical therapy for PA can deliver sustained biochemical and clinical benefits. Early disease detection and adequate dose titration are highly actionable determinants of long-term treatment success.
Influence of Enhanced Administrative Case‐Finding Strategies on Prevalence of Hypertensive Disorders of Pregnancy in Ontario: A Population‐Based Descriptive Study
Johnston, Amy , Petrcich, William, Smith, Graeme N. , Tanuseputro, Peter , Lee, Douglas S. , Coutinho, Thais , Edwards, Jodi D , Smith, Graeme N , Tanuseputro, Peter , Petrcich, William, Edwards, Jodi D.

Mayo Clinic

Journal of the American Heart Association | July 17, 2026 | Volume: 15 | Issue: 14 | Pages: No page available

10.1161/jaha.125.046265 | PMID 42466508 Get It

Background Hypertensive disorders of pregnancy (HDP) are a leading global cause of maternal and fetal morbidity/mortality. Most estimates of HDP occurrence are reported for composite exposures of HDP or preeclampsia alone, with limited disaggregation by obstetrical subgroup (eg, multi‐fetal deliveries). Consequently, our understanding of HDP prevalence and temporal trends remains limited, and methods for identifying specific diagnoses in administrative data remain underexamined. This population‐based descriptive study assessed how enhanced administrative case‐finding definitions influence prevalence estimates of HDP in pregnancy and postpartum. Methods Included were individuals aged ≥18 years discharged from an Ontario hospital following their first obstetrical delivery between April 1, 2002, and December 31, 2017. We calculated overall and annual prevalence estimates and assessed temporal trends for any HDP and major subtypes by case‐finding definitions, stratified by plurality (singleton versus multi‐fetal deliveries). Results Most subjects had a singleton first delivery (n=781 258; 98%); however, HDP was 2.2 to 2.4 times more prevalent in multi‐fetal deliveries. When pre‐pregnancy hypertension was considered during case‐finding, HDP prevalence increased from 193.6 to 207.6 per 1000 multi‐fetal deliveries and from 79.9 to 92.6 per 1000 singleton deliveries. Gestational hypertension was the most common diagnosis in both populations but was nearly twice as common in those who delivered a multiple gestation (94.4–100.0 versus 49.7–53.4 per 1000 deliveries). Prevalence trends differed by coding strategy and plurality. Conclusions Although informative, data from discharge abstracts alone are insufficient for HDP surveillance, particularly for chronic hypertension in pregnancy. Validation studies should assess the accuracy of our case‐finding definitions against suitable reference standards.
Cross-cohort analysis of expression and splicing quantitative trait loci in TOPMed
Blackwell, Thomas W., Kachuri, Linda , Castaldi, Peter J. , Cho, Michael H. , Christenson, Stephanie A. , Durda, Peter , Gabriel, Stacey , Hersh, Craig P. , Huntsman, Scott , Hwang, S.-J., Joehanes, Roby, Johnson, Mari , Li, Xingnan , Lin, Honghuang , Liu, Ching‐Ti , Liu, Yongmei , Mak, Angel C. Y. , Manichaikul, Ani , Paik, David T. , Saferali, Aabida , Smith, Joshua D. , Taylor, Kent D. , Wang, Jiongming , Weinstock, Joshua S. , Weiss, Jeffrey, Wheeler, Heather E. , Zhou, Ying , Zoellner, Sebastian, Mestroni, Luisa , Graw, Sharon , Taylor, Matthew R.G. , Ortega, Victor E. , Johnson, Craig , Gan, Weiniu , Abecasis, Gonçalo , Nickerson, Deborah A. , Ardlie, Kristin G., Woodruff, Prescott G. , Bowler, Russell P. , Meyers, Deborah A. , Reiner, Alex, Kooperberg, Charles , Ziv, Elad , Vasan, Ramachandran S. , Silverman, Edwin K. , Rich, Stephen S., Heard‐Costa, Nancy L. , Tang, Hua, Rotter, Jerome I. , Smith, Albert V. , Aguet, François, Scott, Laura J. , Raffield, Laura M. , Parker, Stephen C.J. , Abe, Namiko, Almasy, Laura, Ament, Seth, Anugu, Pramod, Auer, Paul, Avramopoulos, Dimitrios, Balasubramanian, Adithya, Barr, R. Graham, Barwick, Lucas, Beaty, Terri, Becker, Diane, Becker, Lewis, Beitelshees, Amber, Benos, Takis, Bezerra, Marcos, Bis, Joshua, Brody, Jennifer, Broeckel, Ulrich, Broome, Jai, Bunting, Karen, Buth, Erin, Carey, Vincent, Carty, Cara, Casaburi, Richard, Chaffin, Mark, Chang, Christy, Chang, Yi-Cheng, Chavan, Sameer, Chen, Bo-Juen, Chen, Wei-Min, Choi, Seung Hoan, Chuang, Lee-Ming, Chung, Ren-Hua, Conomos, Matthew, Cornell, Elaine, Crandall, Carolyn, Crapo, James, Curtis, Jeffrey, Damcott, Coleen, David, Sean, Fuentes, Lisa de las, Vries, Paul de, Deka, Ranjan, DeMeo, Dawn, Devine, Scott, Dinh, Huyen, Doddapaneni, Harsha, Duan, Qing, Duggirala, Ravi, Eaton, Charles, Ekunwe, Lynette, Boueiz, Adel El, Emery, Leslie, Farber, Charles, Farek, Jesse, Franceschini, Nora, Frazar, Chris, Fu, Mao, Fullerton, Stephanie M., Fulton, Lucinda, Gao, Shanshan, Gao, Yan, Gass, Margery, Geiger, Heather, Ghosh, Auyon, Gignoux, Chris, Glahn, David, Gogarten, Stephanie, Gong, Da-Wei, Goring, Harald, Grine, Daniel, Gu, C. Charles, Guan, Yue, Hall, Michael, Han, Yi, Harris, Daniel, Heavner, Ben, Herrington, David, Hobbs, Brian, Hong, Elliott, Hoth, Karin, Hsiung, Chao (Agnes), Hu, Jianhong, Hung, Yi-Jen, Huston, Haley, Hwu, Chii Min, Jackson, Rebecca, Jain, Deepti, Johnsen, Jill, Johnston, Rich, Jones, Kimberly, Kessler, Michael, Khan, Alyna, Khan, Ziad, Kim, Wonji, Kimoff, John, Kinney, Greg, Kramer, Holly, Lange, Christoph, Lange, Ethan, Laurie, Cathy, Laurie, Cecelia, LeBoff, Meryl, Lee, Sandra, Lee, Wen-Jane, Levine, David, Lewis, Joshua, Li, Yun, Lin, Xihong, Liu, Simin, Liu, Yu, Make, Barry, Manning, Alisa, Manson, JoAnn, Martin, Lisa, Marton, Melissa, Mathai, Susan, May, Susanne, McArdle, Patrick, McDonald, Merry-Lynn, McFarland, Sean, McGoldrick, Daniel, McHugh, Caitlin, Mei, Hao, Meigs, James, Menon, Vipin, Min, Nancy, Moll, Matt, Momin, Zeineen, Montasser, May, Mychaleckyj, Josyf C, Naik, Rakhi, Naseri, Take, Natarajan, Pradeep, Nelson, Sarah C., Neltner, Bonnie, Nessner, Caitlin, Nkechinyere, Osuji, O'Connell, Jeff, O’Connor, Tim, Ochs-Balcom, Heather, Okwuonu, Geoffrey, Pankow, James, Parker, Cora, Peloso, Gina, Peralta, Juan Manuel, Perez, Marco, Perry, James, Peters, Ulrike, Phillips, Lawrence S, Pollin, Toni, Becker, Julia Powers, Boorgula, Meher Preethi, Psaty, Bruce, Qiao, Dandi, Rafaels, Nicholas, Rajendran, Mahitha, Rasmussen-Torvik, Laura, Ratan, Aakrosh, Reed, Robert, Regan, Elizabeth, Reupena, Muagututi‘a Sefuiva, Robillard, Rebecca, Roselli, Carolina, Ruczinski, Ingo, Runnels, Alexi, Russell, Pamela, Ryan, Kathleen, Sabino, Ester Cerdeira, Salimi, Shabnam, Salvi, Sejal, Salzberg, Steven, Sandow, Kevin, Santibanez, Jireh, Schwander, Karen, Sciurba, Frank, Sériès, Frédéric, Shetty, Amol, Shetty, Aniket, Silver, Brian, Skomro, Robert, Smith, Tanja, Smoller, Sylvia, Snively, Beverly, Stilp, Adrienne M., Storm, Garrett, Streeten, Elizabeth, Su, Jessica Lasky, Sung, Yun Ju, Sylvia, Jody, Szpiro, Adam, Taub, Margaret, Taylor, Simeon, Thornton, Timothy A., Threlkeld, Machiko, Tinker, Lesley, Tirschwell, David, Tiwari, Hemant, Tong, Catherine, Tsai, Michael, Vaidya, Dhananjay, Walker, Tarik, Wallace, Robert, Walts, Avram, Wang, Fei Fei, Wang, Heming, Watson, Karol, Watt, Jennifer, Weng, Lu-Chen, Wessel, Jennifer, Williams, Kayleen, Wilson, Carla, Wilson, James, Winterkorn, Lara, Wong, Quenna, Wu, Baojun, Xu, Huichun, Yanek, Lisa, Yang, Ivana, Zekavat, Seyedeh Maryam, Zhao, Snow Xueyan, Zhao, Wei, Zhu, Xiaofeng, Rich, Stephen S. , Pankow, James S. , Reiner, Alex P. , Aguet, François , Johnson, W. Craig , Ardlie, Kristin , Orchard, Peter , Kachuri, Linda , Castaldi, Peter J , Cho, Michael H , Christenson, Stephanie A , Durda, Peter , Hersh, Craig P , Huntsman, Scott , Hwang, Seungyong , Joehanes, Roby , Johnson, Mari , Li, Xingnan , Lin, Honghuang , Liu, Ching-Ti , Liu, Yongmei , Mak, Angel C Y , Manichaikul, Ani W , Paik, David T , Smith, Joshua D , Taylor, Kent D , Tracy, Russell P , Wang, Jiongming , Wang, Mingqiang , Weinstock, Joshua S , Weiss, Jeffrey , Wheeler, Heather E , Zhou, Ying , Zöllner, Sebastian , Wu, Joseph C , Mestroni, Luisa , Graw, Sharon , Taylor, Matthew R G , Ortega, Victor E , Johnson, W Craig , Gan, Weiniu , Gupta, Namrata , Ardlie, Kristin , Woodruff, Prescott G , Bowler, Russell P , Reiner, Alexander P , Kooperberg, Charles , Ziv, Elad , Vasan, Ramachandran S , Silverman, Edwin K , Rich, Stephen S , Heard-Costa, Nancy , Tang, Hua , Rotter, Jerome I , Smith, Albert V , Levy, Daniel , Aguet, François , Scott, Laura J , Raffield, Laura M , Parker, Stephen C J , Pankow, James S , Tracy, Russell P. , Wu, Joseph C. , Larson, Martin G. , Cupples, L. Adrienne , Abe, Namiko, Almasy, Laura, Ament, Seth, Anugu, Pramod, Auer, Paul, Avramopoulos, Dimitrios, Balasubramanian, Adithya, Barr, R. Graham, Barwick, Lucas, Beaty, Terri, Becker, Diane, Becker, Lewis, Beitelshees, Amber, Benos, Takis, Bezerra, Marcos, Bis, Joshua, Brody, Jennifer, Broeckel, Ulrich, Broome, Jai, Bunting, Karen, Buth, Erin, Carey, Vincent, Carty, Cara, Casaburi, Richard, Chaffin, Mark, Chang, Christy, Chang, Yi-Cheng, Chavan, Sameer, Chen, Bo-Juen, Chen, Wei-Min, Choi, Seung Hoan , Chuang, Lee-Ming, Chung, Ren-Hua, Conomos, Matthew, Cornell, Elaine, Crandall, Carolyn, Crapo, James, Curtis, Jeffrey, Damcott, Coleen, David, Sean, Fuentes, Lisa de las, Vries, Paul de, Deka, Ranjan, DeMeo, Dawn, Devine, Scott, Dinh, Huyen, Doddapaneni, Harsha, Duan, Qing, Duggirala, Ravi, Eaton, Charles, Ekunwe, Lynette, Boueiz, Adel El, Emery, Leslie, Farber, Charles, Farek, Jesse, Franceschini, Nora, Frazar, Chris, Fu, Mao, Fullerton, Stephanie M., Fulton, Lucinda, Gao, Shanshan, Gao, Yan, Gass, Margery, Geiger, Heather, Ghosh, Auyon, Gignoux, Chris, Glahn, David, Gogarten, Stephanie, Gong, Da-Wei, Goring, Harald, Grine, Daniel, Gu, C. Charles, Guan, Yue, Hall, Michael, Han, Yi, Harris, Daniel, Heavner, Ben, Herrington, David, Hobbs, Brian, Hong, Elliott, Hoth, Karin, Hsiung, Chao (Agnes), Hu, Jianhong, Hung, Yi-Jen, Huston, Haley, Hwu, Chii Min, Jackson, Rebecca, Jain, Deepti, Johnsen, Jill, Johnston, Rich, Jones, Kimberly, Kessler, Michael, Khan, Alyna, Khan, Ziad, Kim, Wonji, Kimoff, John, Kinney, Greg, Kramer, Holly, Lange, Christoph, Lange, Ethan, Laurie, Cathy, Laurie, Cecelia, LeBoff, Meryl, Lee, Sandra, Lee, Wen-Jane, Levine, David, Lewis, Joshua, Li, Yun, Lin, Xihong, Liu, Simin, Liu, Yu, Make, Barry, Manning, Alisa, Manson, JoAnn, Martin, Lisa, Marton, Melissa, Mathai, Susan, May, Susanne, McArdle, Patrick, McDonald, Merry-Lynn, McFarland, Sean, McGoldrick, Daniel, McHugh, Caitlin, Mei, Hao, Meigs, James, Menon, Vipin, Min, Nancy, Moll, Matt, Momin, Zeineen, Montasser, May, Mychaleckyj, Josyf C, Naik, Rakhi, Naseri, Take, Natarajan, Pradeep, Nelson, Sarah C., Neltner, Bonnie, Nessner, Caitlin, Nkechinyere, Osuji, O'Connell, Jeff, O’Connor, Tim, Ochs-Balcom, Heather, Okwuonu, Geoffrey, Parker, Cora, Peloso, Gina, Peralta, Juan Manuel, Perez, Marco, Perry, James, Peters, Ulrike, Phillips, Lawrence S, Pollin, Toni, Becker, Julia Powers, Boorgula, Meher Preethi, Psaty, Bruce, Qiao, Dandi, Rafaels, Nicholas, Rajendran, Mahitha, Rasmussen-Torvik, Laura, Ratan, Aakrosh, Reed, Robert, Regan, Elizabeth, Reupena, Muagututi‘a Sefuiva, Robillard, Rebecca, Roselli, Carolina, Ruczinski, Ingo, Runnels, Alexi, Russell, Pamela, Ryan, Kathleen, Sabino, Ester Cerdeira, Salimi, Shabnam, Salvi, Sejal, Salzberg, Steven, Sandow, Kevin, Santibanez, Jireh, Schwander, Karen, Sciurba, Frank, Sériès, Frédéric , Shetty, Amol, Shetty, Aniket, Silver, Brian, Skomro, Robert, Smith, Tanja, Smoller, Sylvia, Snively, Beverly, Stilp, Adrienne M., Storm, Garrett, Streeten, Elizabeth, Su, Jessica Lasky, Sung, Yun Ju, Sylvia, Jody, Szpiro, Adam, Taub, Margaret, Taylor, Simeon, Thornton, Timothy A., Threlkeld, Machiko, Tinker, Lesley, Tirschwell, David, Tiwari, Hemant, Tong, Catherine, Tsai, Michael, Vaidya, Dhananjay, Walker, Tarik, Wallace, Robert, Walts, Avram, Wang, Fei Fei, Wang, Heming, Watson, Karol, Watt, Jennifer, Weng, Lu-Chen, Wessel, Jennifer, Williams, Kayleen, Wilson, Carla, Wilson, James, Winterkorn, Lara, Wong, Quenna, Wu, Baojun, Xu, Huichun, Yanek, Lisa, Yang, Ivana, Zekavat, Seyedeh Maryam, Zhao, Snow Xueyan, Zhao, Wei, Zhu, Xiaofeng

Mayo Clinic

Science | July 16, 2026 | Volume: 393 | Issue: 6808 | Pages: No page available

10.1126/science.adx2989 | PMID 42462027 Get It

Most genetic variants associated with complex traits are hypothesized to regulate gene expression. To understand the genetics underlying gene expression variability, we characterized 14,324 RNA-sequencing samples from the Trans-Omics for Precision Medicine program and performed expression and splicing quantitative trait locus (e/sQTL) analyses in six tissues and cell types, including whole blood ( n = 6454) and lung ( n = 1291). We detected tens of thousands of secondary cis-e/sQTLs, showing that secondary cis-e/sQTL discovery remains unsaturated. We fine-mapped UK Biobank–derived genome-wide association study (GWAS) signals from 164 traits and identified e/sQTL colocalizations for 10,611 GWAS signals, including 7096 that colocalize with secondary e/sQTLs. Our results suggest that even larger e/sQTL analyses will uncover additional secondary e/sQTLs, further benefiting GWAS interpretation.
Noninvasive electrical neuromodulation involving vagus nerve mechanism for functional constipation and irritable bowel syndrome with constipation
Liu, Jie , Lv, Chanlan, Zhu, Xiuli, Hong, Na, Huang, Yizhou , Sun, C J , Yan, Yan, Ys, Yu , Wang, Yichen, Huang, Yuting

Mayo Clinic

Therapeutic Advances in Gastroenterology | July 16, 2026 | Volume: 19 | Issue: No issue available | Pages: No page available

10.1177/17562848261469142 | PMID 42491410 Get It

Functional constipation (FC) and irritable bowel syndrome with constipation (IBS-C) are prevalent disorders of gut–brain interaction with limited effective treatments. The vagus nerve exerts considerable influence on the gastrointestinal (GI) tract, indicating that noninvasive electrical neuromodulation targeting this nerve could provide a promising therapeutic avenue for both FC and IBS-C. This review explores several emerging noninvasive neuromodulation techniques involving the vagus nerve, such as transcutaneous auricular vagal nerve stimulation, percutaneous electrical nerve field stimulation, and transcutaneous electrical acustimulation. The clinical applications of these methods in managing FC and IBS-C are evaluated. Existing evidence supports the efficacy and safety of noninvasive neuromodulation in relieving symptoms of these conditions. Future investigations should aim to refine these techniques, advance device technology, and further clarify the mechanisms of action.